Oncology and Cancer

About Conference

Welcome Message

Join us at the 6th International Conference on Oncology and Cancer, a premier global platform bringing together leading oncologists, researchers, healthcare professionals, and industry experts to explore the latest breakthroughs in cancer science and treatment.

Set in the iconic city of Paris, this conference will serve as a hub for innovation, collaboration, and knowledge exchange, aiming to redefine the future of cancer care.

 About the Conference

The 6th International Conference on Oncology and Cancer, scheduled for November 24–25, 2026 in Paris, France, is a premier global forum dedicated to advancing research and innovation in cancer science and treatment. This conference brings together leading oncologists, researchers, healthcare professionals, academicians, and industry experts from around the world to share knowledge, present cutting-edge research, and discuss emerging trends in oncology. With a strong focus on transformative technologies such as artificial intelligence, precision medicine, immunotherapy, and advanced diagnostics, the event aims to address current challenges and explore future directions in cancer care. Attendees will benefit from insightful keynote sessions, interactive discussions, and valuable networking opportunities, all designed to foster collaboration and accelerate progress toward more effective, personalized, and accessible cancer treatments.

 Why Attend?

•  Keynote Talks from global experts
• Latest Research Presentations
• Networking Opportunities with top professionals
• Workshops & Panel Discussions
• Global Exposure & Collaboration
•  Certificate & Recognition Opportunities

Who Should Attend?

• Oncologists & Physicians
• Researchers & Scientists
• Medical Students & Academicians
• Pharma & Biotech Professionals
• Healthcare Innovators & Startups
• Policy Makers & NGOs

Key Highlights

• AI in Cancer Detection & Treatment
• Next-Gen Immunotherapy Advances
• Personalized & Precision Medicine
• Cancer Genomics & Biomarkers
• Clinical Trials & Drug Development
• Global Cancer Prevention Strategies

 Call for Abstracts

We invite researchers and professionals to submit their abstracts and showcase their work on a global stage. Selected papers will be presented and recognized for excellence.

Why Paris?

Experience world-class science in one of the most beautiful cities in the world. Paris offers the perfect blend of culture, innovation, and inspiration, making your conference experience truly unforgettable.

advancements in cancer care.

What Attendees Gain?

Cutting-Edge Knowledge

Gain insights into the latest advancements in AI, precision medicine, and modern cancer treatments. Stay updated with emerging technologies shaping oncology. Enhance your clinical and research understanding.

Insights from Global Experts

Learn from leading oncologists and industry experts through keynote sessions. Gain practical knowledge and real-world perspectives. Interact directly through discussions and Q&A.

International Networking

Connect with global professionals, researchers, and organizations. Build collaborations and expand your professional network. Explore new career and research opportunities.

Research Presentation & Exposure

Showcase your research to an international audience. Receive expert feedback to improve your work. Increase your visibility in the scientific community.

Recognition & Career Advancement

Earn awards and certificates to strengthen your profile. Gain recognition for your contributions. Support your long-term career growth in oncology.

Conference Highlights

• Latest Advances in Cancer Research & Treatment
• AI & Precision Medicine in Oncology
• Clinical Trials & Innovative Drug Development
• International Networking & Collaboration Opportunities
• Awards & Recognition for Best Research and Young Scientists

Scientific Sessions & Tracks

Track 1: Cancer Biology & Tumor Microenvironment

This track focuses on the fundamental biological mechanisms driving cancer development and progression. It explores the complex interactions between tumor cells and their surrounding microenvironment, including immune and stromal components. Key areas include tumor heterogeneity, angiogenesis, hypoxia, and immune evasion. Recent advances in molecular oncology will be highlighted to understand cancer growth and resistance to therapies. The session also emphasizes the impact of the microenvironment on treatment outcomes. Emerging technologies used to study tumor ecosystems will be discussed. Insights into identifying novel therapeutic targets will be presented. Overall, this track aims to support the development of more effective and targeted cancer treatments.

Track 2: AI & Machine Learning in Oncology

This track highlights the transformative role of artificial intelligence and machine learning in cancer care. It covers AI-driven diagnostics, predictive analytics, and clinical decision support systems. Discussions include imaging analysis, pathology automation, and real-time data interpretation. The session also explores how AI enhances treatment planning and patient outcomes. Ethical considerations and data privacy challenges will be addressed. Integration of AI into clinical workflows will be emphasized. Participants will gain insights into future AI innovations in oncology. Overall, this track focuses on smarter, faster, and more accurate cancer care solutions.

Track 3: Precision Medicine & Personalized Cancer Treatment

This track focuses on tailoring cancer treatments based on individual genetic and molecular profiles. It highlights advances in targeted therapies and patient-specific treatment strategies. Discussions include biomarker-driven approaches and customized drug selection. The role of genomics in improving treatment efficacy will be explored. Challenges in implementing personalized medicine will also be addressed. The session emphasizes improved patient outcomes and reduced side effects. Emerging tools enabling precision oncology will be showcased. Overall, it promotes a patient-centric approach to cancer care.

Track 4: Cancer Genomics, Epigenetics & Biomarkers

This track explores the genetic and epigenetic alterations driving cancer development. It focuses on biomarker discovery for early detection and targeted therapy. Discussions include DNA mutations, gene expression, and epigenetic modifications. The role of biomarkers in diagnosis and prognosis will be highlighted. Advances in sequencing technologies will be covered. The session also addresses challenges in clinical translation. Participants will gain insights into precision diagnostics. Overall, this track supports the advancement of personalized oncology.

Track 5: Immunotherapy & Targeted Therapy Advances

This track covers breakthroughs in immunotherapy and targeted cancer treatments. It highlights immune checkpoint inhibitors, CAR-T cell therapy, and monoclonal antibodies. Discussions include mechanisms of immune response and resistance. The session explores combination therapies for enhanced effectiveness. Advances in targeted drug delivery will also be discussed. Clinical outcomes and ongoing research will be reviewed. Participants will learn about next-generation therapies. Overall, this track focuses on innovative approaches to cancer treatment.

Track 6: Clinical Trials & Translational Cancer Research

This track focuses on bridging laboratory research with clinical applications. It highlights the design and execution of cancer clinical trials. Discussions include regulatory challenges and patient recruitment strategies. The session explores translating discoveries into effective treatments. Advances in trial methodologies will be covered. Ethical considerations in clinical research will be addressed. Participants will gain insights into real-world applications. Overall, this track supports faster innovation in cancer therapies.

Track 7: Early Detection, Screening & Diagnostic Technologies

This track emphasizes the importance of early cancer detection for improved survival rates. It covers advanced screening methods and diagnostic tools. Discussions include imaging technologies and liquid biopsies. The role of biomarkers in early diagnosis will be highlighted. Innovations in non-invasive detection techniques will be explored. The session also addresses accessibility and affordability challenges. Participants will gain knowledge of emerging diagnostic solutions. Overall, this track promotes proactive cancer management.

Track 8: Radiation Oncology & Advanced Radiotherapy Techniques

This track focuses on modern radiation therapy approaches in cancer treatment. It highlights precision radiotherapy and image-guided techniques. Discussions include advancements in dose optimization and treatment planning. The session explores minimizing damage to healthy tissues. Emerging technologies like proton therapy will be covered. Clinical outcomes and safety measures will be discussed. Participants will learn about next-generation radiotherapy solutions. Overall, this track enhances effective cancer treatment strategies.

Track 9: Surgical Oncology & Minimally Invasive Procedures

This track explores advanced surgical techniques in cancer treatment. It highlights minimally invasive and robotic-assisted surgeries. Discussions include improved patient recovery and reduced complications. The session covers innovations in surgical planning and precision. Advances in tumor removal techniques will be presented. Integration with other treatment modalities will be discussed. Participants will gain insights into modern surgical practices. Overall, this track focuses on improving surgical outcomes.

Track 10: Hematologic Malignancies & Blood Cancers

This track focuses on cancers affecting blood and bone marrow. It covers leukemia, lymphoma, and multiple myeloma. Discussions include diagnosis, treatment strategies, and disease management. Advances in targeted therapies and stem cell transplantation will be explored. The session highlights challenges in treating blood cancers. Emerging research and clinical outcomes will be discussed. Participants will gain insights into innovative therapies. Overall, this track supports advancements in hematologic oncology.

Track 11: Breast, Lung, Colorectal & Prostate Cancer Studies

This track covers the most prevalent types of cancers worldwide. It highlights recent research in diagnosis, treatment, and prevention. Discussions include risk factors and screening strategies. Advances in targeted therapies will be explored. The session focuses on improving survival and quality of life. Clinical case studies and outcomes will be presented. Participants will gain practical insights into treatment approaches. Overall, this track addresses major global cancer challenges.

Track 12: Pediatric Oncology & Rare Cancers

This track focuses on cancers affecting children and rare cancer types. It highlights unique challenges in diagnosis and treatment. Discussions include specialized therapies and patient care strategies. Advances in research for rare cancers will be explored. The session emphasizes improving survival rates in pediatric cases. Ethical considerations in treatment will be addressed. Participants will gain insights into innovative care approaches. Overall, this track supports advancements in specialized oncology fields.

Track 13: Cancer Prevention, Lifestyle & Public Health

This track emphasizes strategies to reduce cancer risk through prevention. It covers lifestyle factors such as diet, exercise, and tobacco control. Discussions include public health policies and awareness programs. The role of early intervention will be highlighted. The session explores community-based prevention strategies. Global initiatives for cancer control will be discussed. Participants will gain insights into reducing cancer burden. Overall, this track promotes healthier populations.

Track 14: Oncology Nursing & Palliative Care

This track focuses on patient-centered care in oncology nursing. It highlights pain management and supportive care strategies. Discussions include improving quality of life for cancer patients. The session covers emotional and psychological support. Advances in palliative care practices will be explored. The role of nurses in treatment and recovery will be emphasized. Participants will gain practical care insights. Overall, this track enhances compassionate cancer care.

Track 15: Pharma Innovations & Drug Discovery in Oncology

This track explores advancements in cancer drug development. It highlights new therapeutic agents and treatment approaches. Discussions include drug design, testing, and approval processes. The session covers challenges in oncology drug discovery. Emerging technologies in pharmaceutical research will be discussed. Collaboration between industry and academia will be emphasized. Participants will gain insights into future drug innovations. Overall, this track drives progress in cancer therapeutics.

Track 16: Digital Health, Telemedicine & Oncology Data Science

This track focuses on digital transformation in cancer care. It highlights telemedicine and remote patient monitoring. Discussions include data analytics and health informatics. The session explores improving access to care through technology. Challenges in data security and integration will be addressed. Emerging digital tools in oncology will be showcased. Participants will gain insights into modern healthcare solutions. Overall, this track promotes technology-driven cancer care.

Market Analysis

The global oncology market is projected to exceed $500 billion by 2030, growing at a CAGR of 8–10%, driven by rising cancer prevalence and continuous innovation in treatment approaches. Each year, over 20 million new cancer cases are diagnosed globally, with more than 10 million deaths, highlighting the urgent need for advanced therapies and early detection strategies. Cancer drug spending has already surpassed $200 billion annually, reflecting strong investment in research and development.

Immunotherapy is one of the fastest-growing segments, expanding at over 12% CAGR, while precision medicine now contributes 30–35% of oncology treatment strategies in developed healthcare systems. Additionally, more than 60% of ongoing clinical trials are focused on targeted and personalized therapies, indicating a major shift toward more effective and patient-specific cancer care solutions.

The adoption of artificial intelligence in oncology is accelerating rapidly, with the AI healthcare market growing at a 35–40% CAGR, transforming diagnostics, imaging, and treatment planning. Emerging markets are also witnessing strong growth at 10–12% annually due to improving healthcare infrastructure, government initiatives, and increased awareness, creating significant opportunities for innovation, collaboration, and global advancements in cancer care.